A Novel Insight Into the Fate of Cardiomyocytes in Ischemia-Reperfusion Injury: From Iron Metabolism to Ferroptosis

Jing-yan Li1, Shuang-qing Liu2, Ren-qi Yao2, Ying-ping Tian1* and Yong-ming Yao1,2*

1Department of Emergency, The Second Hospital of Hebei Medical University, Shijiazhuang, China, 2Translational Medicine Research Center, Medical Innovation Research Division and Fourth Medical Center of the Chinese PLA General Hospital, Beijing, China

Ischemia-reperfusion injury (IRI), critically involved in the pathology of reperfusion therapy for myocardial infarction, is closely related to oxidative stress the inflammatory response, and disturbances in energy metabolism. Emerging evidence shows that metabolic imbalances of iron participate in the pathophysiological process of cardiomyocyte IRI [also termed as myocardial ischemia-reperfusion injury (MIRI)]. Iron is an essential mineral required for vital physiological functions, including cellular respiration, lipid and oxygen metabolism, and protein synthesis. Nevertheless, cardiomyocyte homeostasis and viability are inclined to be jeopardized by iron-induced toxicity under pathological conditions, which is defined as ferroptosis. Upon the occurrence of IRI, excessive iron is transported into cells that drive cardiomyocytes more vulnerable to ferroptosis by the accumulation of reactive oxygen species (ROS) through Fenton reaction and Haber–Weiss reaction. The increased ROS production in ferroptosis correspondingly leads cardiomyocytes to become more sensitive to oxidative stress under the exposure of excess iron. Therefore, ferroptosis might play an important role in the pathogenic progression of MIRI, and precisely targeting ferroptosis mechanisms may be a promising therapeutic option to revert myocardial remodeling. Notably, targeting inhibitors are expected to prevent MIRI deterioration by suppressing cardiomyocyte ferroptosis. Here, we review the pathophysiological alterations from iron homeostasis to ferroptosis together with potential pathways regarding ferroptosis secondary to cardiovascular IRI. We also provide a comprehensive analysis of ferroptosis inhibitors and initiators, as well as regulatory genes involved in the setting of MIRI.

Keywords: ischemia-reperfusion injury, cardiomyocyte, cell death, ferroptosis, iron metabolism

INTRODUCTION

To date, revascularization is commonly regarded as one of the efficacious treatments for ischemic cardiomyopathy in patients with critically acute myocardial infarction (Yang et al., 2018). However, reperfusion therapy is inevitably complicated with myocardial ischemia-reperfusion injury (MIRI), which is responsible for increased mortality and poor outcomes in myocardial infarction, thereby reducing the preponderance of reperfusion therapy to a large extent (Bell and Yellon, 2011). It has been demonstrated that ischemia-reperfusion injury (IRI) is especially involved in persistent...
Impairment of cardiac function, followed by myocardial remodeling. Therefore, timely recognition and prompt interference for MIRI are the currently clinical incidents that need to be urgently resolved to improve the survival and prognosis of myocardial infarction patients. Dysfunction in cardiomodulatory response compromised by IRI impairs cardiometabolism, including oxidative stress, systemic inflammation, calcium metabolic disorders, mitochondrial damage, and iron overload, which ultimately results in a vicious cycle between progressive disturbance of cardiomyocyte metabolism and irreversible myocardial remodeling (Turer and Hill, 2010). Deep insights into the interplay between IRI and intracellular metabolism as well as cell death in cardiomyocytes are of great importance in extending the knowledge of the pathogenesis and development of MIRI.

As we know, iron is considered an essential mineral that serves as a prerequisite in pivotal biological processes, including oxygen transfer, enzymatic catalyzed reaction, aerobic respiration, lipid peroxidation, and intracellular metabolism (Hirst, 2013). Iron deficiency jeopardizes the contractility of cardiomyocytes by subduing mitochondrial function and decreasing energy generation, resulting in impairment of cardiac function (Hoes et al., 2018). Upon the physiological state, iron is capable of playing an important role in energy metabolism through multiple ways to enter cardiomyocytes, being utilized for storage or transported into the mitochondrion to take part in biosynthetic reaction (Valko et al., 2016). Under the challenge of continuous stress or decompensatory response however iron reversely drives a poisonous property resulting from the overproduction of reactive oxygen species (ROS), which collapses the balance between generation and depletion in free radicals via the Fenton reaction and Haber–Weiss reaction (Valko et al., 2016). Uncontrolled accumulation of iron concentration and redox efficacy of ferrous (Fe²⁺) ions facilitate a perniciously metabolic network in cardiomyocytes, contributing to lipid peroxidation along with ROS overproduction, which exert a great threat to the function of basic cellular mechanisms (Gammella et al., 2016; He et al., 2019). Increased mitochondrial iron-related ROS generation is another regulatory contributor to both malfunction of intrinsic mitochondria and cardiac tissue injury. Mitochondrial iron is deemed as the major factor determining cardiomyocyte fate as evidenced by approximately one-third of cardiomyocyte iron reserves in the mitochondria. Moreover, it has been reported that the iron content in cardiomyocyte mitochondria is 50% higher than that of the other cells (Wofford et al., 2017). Increasing clinical studies have suggested that the level of cardiomyocyte iron is a prognostic factor of MIRI accounting for the deposition of iron in cardiac tissue in the occurrence of MIRI. Additionally, the impeded erythrocyte flow in the obstructive region might lead red blood cells to be lysed, resulting in the accumulation of iron from hemoglobin, which can eventually generate excessive ROS and trigger pathological events of MIRI. As is hypothesized that iron deposition might be recognized as an integral element of pathophysiology for triggering MIRI and increasing mortality risk, it is of great significance to clarify the underlying mechanisms of iron-mediated cell death to further provide potential targets for MIRI therapy.

As we all know, no matter what mechanisms are involved in the pathophysiology of MIRI, the final foreordination of the injured cardiomyocyte is the distinct forms of programmed cell death, which have been identified to play an essential role in MIRI, namely, apoptosis, necroptosis, pyroptosis, and ferroptosis. Over the past decades, regarded as the main types of cell death for cardiomyocytes, apoptosis is considered a form of programmed cell death, while necrosis is thought to be an accidental and uncontrolled type of cell death. In recent decades however, necrosis is precisely regulated by differently signaling pathways, including necroptosis, ferroptosis, pyroptosis, oxtosis, and parthanatos. Currently, noxious iron overload has been reported to induce non-apoptosis cell death, defined as ferroptosis, which presents with a deteriorative cross talk between lipid peroxidation, and a mass of ROS accumulation depended on excessive iron, together with the dominating causes of reduction in glutathione synthesis and deactivation of enzyme glutathione peroxidase 4 (GPX4) (Dixon et al., 2012). Indeed, multiple factors are involved in the pathogenesis of cardiac I/R injury implicated by ferroptosis, such as amino acid and lipid metabolism as well as iron mobilization and peroxidation through Fenton reaction (Fang et al., 2019). The regulatory effects of other factors, including activity of GPX4, ferroptosis-associated endoplasmic reticulum stress (ERS), and the mammalian target of rapamycin (mTOR)-mediated iron transport proteins, are also noteworthy but remain controversial (Baba et al., 2018; Li et al., 2020). From a molecular perspective, both ferroptosis-related initiators and inhibitors might be the potential targets for treatment of MIRI since ferroptosis accompanied by excess iron is confirmed to be the leading cause of cardiomyocyte death. Suppressing ferroptosis to prevent cardiac cell death and alleviate cardiac remodeling might become an efficacious therapeutic strategy for MIRI.

### Iron Homeostasis and Its Role in Cardiomyocytes

The pathophysiological progression of cardiomyocyte injury reportedly results from a disorder of iron homeostasis attributed to the overproduction of ROS and formation of the mitochondrial permeability transition pore (mPTP), ultimately leading to the induction of cardiomyocyte death (Morciano et al., 2015; Pell et al., 2016). In fact, hyperactivation of hypoxia-inducible factor (HIF) upregulates the mitochondrial ferritin (FtM) expression of transferrin receptor 1 (TfR1), followed by increased iron accumulation, which traps cardiomyocytes into a vicious cycle of exacerbated ROS-induced impairment (Tang et al., 2008). A unique cohort of FtMt, featured on ferrooxidase activity and regulatory capacity of iron metabolism in mitochondria, acts as a prime contributor to myocardial vitality and ROS regulation in IRI (Wood, 2008; Wu et al., 2016). Since most of mitochondrial ROS arise from redox reaction in the initial stage of oxidative stress, it is reasonable to predicate that mitochondrial function serves as a bridge.
connecting iron homeostasis to ROS production during the occurrence of MIRI, suggesting that reversal of mitochondrial iron–associated peroxidation reaction might be one of the beneficial interferences with MIRI. Notably, the schematic diagram of iron homeostasis in cardiomyocytes and mitochondria is shown in Figure 1.

**Iron Transport in Cardiomyocytes**

Cardiomyocyte intussuscepts iron mainly depending on ferritin (FT), either by means of combination with TfR1 and subsequently receptor-mediated endocytosis, or through the calcium channels and zinc transporters in the cardiac plasma membrane, which are mediated by divalent metal transporter 1 (DMT-1) protein (Hentze et al., 2010). In addition to being stored in FT cores in normal circumstances, ferrous ion can be mobilized and released to peripheral circulation via ferroportin (FPN), which is located on the basolateral membrane of enterocytes (Oudit et al., 2003). Upon entrance into the cardiomyocytes, iron is stored in the labile iron pool (LIP), where the level of iron is maintained stably on a normal range but abruptly increases under exposure to the pathological state, acting as an intermediate to promote heme and iron–sulfur cluster production in the mitochondrion through the biosynthetic pathway (Lane et al., 2015). Iron in LIP can be utilized for storage in FT, which serves as a ubiquitous intracellular buffer to prevent iron deficiency and iron overload, contributing to its efficacy in reserving as much as 5,000 atoms of iron in a soluble form and transporting iron to the requisite site (Watt, 2013). FT, composed of 24 subunits of both ferritin heavy chain (FTH) and ferritin light chain (FTL), is regarded as a key factor implicated with iron homeostasis for the reason that it combines and segregates iron in the case of redundant iron importing to protect against oxidative stress, whereas it releases and transports iron when suffering iron deficiency (Kawabata, 2019).

Notably, intracellular iron concentration and homeostasis are affected by several key regulators. Since the peroxidative peculiarity of iron prompts it to be a redox catalyst for the generation of noxious ROS, intracellular iron is exactly regulated by the ROS-dependent cell signaling pathway to maintain biological function. One of these catalytic responses is initiated in the Fenton reaction, for example, stimulating hydroxyl radical (HO) production, and another contributor concentrates on ferrous ion–mediating lipid peroxidation response, in turn inducing the accumulation of lipid radicals (Aisen et al., 2001). Moreover, transcriptional modification after the interconnection between iron regulatory proteins (IRPs) and iron responsive elements (IREs) is involved in the regulated mechanisms with regard to the cellular iron homeostatic process in iron intake, reservation, and release by modulating the synthetic function of iron metabolism–associated proteins (Haddad et al., 2017). Under the low content of cellular iron, bidirectional IRPs are responsible for either stabilizing the mRNA expression of TfR1 and DMT-1 to facilitate iron indrawal, or...
conducting a suppressed impact on mRNA translation of FT in order to inhibit iron storage (Paterek et al., 2019). Additionally, the degradation of FPN has been proven to be independently related to hepcidin in cardiomyocytes, and it accounts for the inactivation of FPN, eventually resulting in reduced iron release. Actually, cardiac hepcidin is found to be a major cause for iron metabolism in cardiomyocytes, and it exhibits a distinction from systemic iron regulation due to its autologous secretory function that promotes cardiac hepcidin protein upregulation rather than downregulation onset of hypoxia (Lakhal-Littleton et al., 2016). Thus, the fact that only one FPN protein is available for iron exporting during iron accumulation might further confirm cardiomyocytes to be more sensitive to iron overload than other cell types.

The Role of Iron Metabolism in Myocardial Mitochondria

The mitochondrial, known as an essential organelle for systemic energy metabolism, confers an important impact on iron homeostasis and modulation of myocardial damage during IRI (Richardson et al., 2010; Lesniesky et al., 2017; Vela, 2020). It has been documented that mitochondria provide available sites for heme synthesis and iron–sulfur cluster (ISC) generation, with formation of heme and ISC proteins to be integrated in the mitochondrial oxidative phosphorylation system, which supplies a physiological necessity of cardiac activity for continuous energy through catalyzing electron transport of oxidative iron (Paul et al., 2017). Thus, iron concentration in mitochondria is closely related to the fate of cardiomyocytes since the level of mitochondrial iron in cardiac myocytes is remarkably higher than other cells. As reported by Wofford et al., insufficient iron might impose restriction on energy export, whereas uncontrolled iron overload could lead to a disruption of the mitochondrion via redundant ROS generation (Kruszewski, 2003; Wofford et al., 2017). Along with ROS-associated toxicity in mitochondria, the productions of poisonous hydroxyl radicals, as a result of the reaction between ROS and mitochondria, contribute to depolarization in mitochondrial membrane potential (MMP) and openness in the mitochondrial permeability pore, thereby leading to aberrant morphology of mitochondrial swelling as well as mitochondrial dysfunction (Sripathchwanee et al., 2014; Chan et al., 2018).

MOLECULAR MECHANISMS OF IRON METABOLISM IN CARDIOMYOCYTE IRI

Iron metabolism imbalance, especially iron overload, has been demonstrated to be implicated in the pathology of cardiomyocyte IRI, resulting from the driving forces of excessive ROS and oxygen free radicals that attribute to antioxidant system disrupt onset of constant exposure to IRI (Zhou et al., 2015; Cadenas, 2018). Inherently, this pathological process further aggravates oxidative stress accompanied by myocardial membrane damage and cardiovascular endothelial dysfunction (Dongó et al., 2011). In the early stage of ischemia and reperfusion, intracellular iron is conductive to be released in the acid internal environment of cardiomyocytes, augmenting iron-mediated Fenton reaction, which converses hyporeactive hydrogen peroxide to hyperreactive hydroxyl radicals (Williams et al., 1991). In this case, the administration of iron inhibitors at the initial phase of reperfusion might diminish free radical generation and attenuate cardiomyocyte IRI (Drossos et al., 1995).

The Pathophysiology of Cardiomyocyte IRI

Increasing evidence indicates that multiple pathophysiological factors are involved in the development of MIRI, including oxidative stress, endothelial cell inflammation, calcium overload, and energy metabolism disorder. Cardiomyocyte IRI is commonly accompanied by redundant oxygen-free radicals and accumulated ROS after cardiovascular reperfusion, which finally evokes the peroxidation of proteins, lipids, and nucleic acids. These endogenous superoxide products can further accelerate membrane injury and organelle dysfunction (Matsushima et al., 2014). Along with hyperactivated inflammation compromised by conglutination and infiltration of neutrophils, cardiomyocyte IRI unexpectedly worsens as a result of robust feedback on increased metabolism of arachidonic acid, in turn leading to a massive production of inflammatory cytokines (Vinten-Johansen et al., 2007; Boag et al., 2017). During cardiomyocyte I/R injury, high levels of pro-inflammatory cytokines promote either the myocardial tissue to maintain a pro-inflammatory state or endothelial cells to induce autophagy, eventually exposing cardiomyocytes to a more vulnerable damage in structure and function (Russo et al., 2017; Schanze et al., 2019). Intracellular calcium, with the peculiar capacity of maintaining cardiomyocyte functions, appears to be more sensitive to reperfusion, and it is largely overloaded when cardiomyocytes suffer IRI (Verkhratsky and Parpura, 2014). Similar to excessive amounts of iron, calcium overload suppresses excitability and contractility of cardiomyocytes, attributed to the combination
between calcium and troponin, which finally debilitates the contraction of myocardial cells (Grueter et al., 2006). With regard to energy metabolism during cardiomyocyte IRI, ATP produced by glycolysis is considered to be the primary source of energy for the maintenance of cardiomyocyte vitality at the initial phase of reperfusion. Inevitably, this action causes cardiomyocytes to suffer a vicious cross talk between lactate accumulation and the acidic environment, resulting in fatty acid peroxidation together with an energy metabolism disorder (Tian et al., 2019). Taken together, cardiomyocyte IRI depends on the energy metabolism disorder initiated in the ischemia-hypoxia setting and enhances production of oxygen free radicals, which indirectly induce calcium along with inflammation, leading to mitochondrial damage (Figure 2).

The Mediators of Iron Metabolism in Cardiomyocyte IRI

It has been reported that multiple iron metabolism–associated factors are thought to be associated with the pathogenesis of cardiomyocyte IRI, including HIF and FTH signaling pathways and mitochondrial iron protein–regulated pathway (Table 1). The HIF, for instance, presents with visible hyperactivation, which, in turn, upregulates iron TfR1 expression and causes iron overload during cardiomyocyte IRI.

**TABLE 1 | Mediators of iron metabolism in MIRI-associated diseases.**

| Molecule | Regulatory effects |
|----------|-------------------|
| HIF      | Enhances TfR1 expression and exasperates iron overload and ROS production |
| FTH      | Binds iron and suppresses cardiomyocyte capacity |
| MFRN     | Regulates mitochondrial iron import |
| MCU      | Regulates mitochondrial calcium unipporter |
| ABCB8    | Augments mitochondrial iron output |
| IRP      | Modulates iron intake, reservation, and release |
| IRE      | Regulates the synthesis of iron metabolism–associated proteins |
| FPN      | Mobilizes and releases ferrous ion to peripheral circulation |
| FtMt     | Inputs iron and redistributes iron from the cytosol to mitochondria |
| DMT-1    | Promotes iron indrawal and inputs iron |

Abbreviations: HIF, hypoxia-inducible factor; FTH, ferritin heavy chain; MFRN, mitoferrin 2; MCU, mitochondrial calcium unipporter; ABCB8, ATP-binding cassette subfamily B member 8; IRP, iron regulatory proteins; IRE, iron-responsive elements; FPN, ferroportin; FtMt, mitochondrial ferritin; and DMT-1, divalent metal transporter 1.
eventually exasperating ROS-induced peroxidative injury (Zhang et al., 2019a). Further evidence has shown that the administration of cardiomyocytes with iron chelators after I/R injury is beneficial for the reversion on myocardiac malfunction (Paraskevaidis et al., 2005). Another mediator of FTH, as observed trending a down-expressed toward in the mouse model of MIRI, exerted a suppressed effect on the capacity of cardiomyocytes in binding free iron, leading to oxidative stress and even cell death (Omiya et al., 2009). Unique cohorts of mitochondrial iron proteins are demonstrated to complicate modulating cardiomyocyte IRI and play important roles in survival and prognosis of cardiomyocytes via controlling ROS generation. For instance, mitochondrial iron import is regulated by mitoferrin 2 (MFRN) and mitochondrial calcium uniporter (MCU), whereas its export is modulated via ABCB proteins (Ichikawa et al., 2012). The same verification goes for ATP-binding cassette subfamily B member 8 (ABCB8) that upregulated expression of ABCB8 through genetic modification is identified to effectively promote mitochondrial iron output and finally protect cardiomyocytes against IRI (Chang et al., 2016). Hence, mitochondrial iron regulators might become effective targets for improving outcomes in the setting of MIRI (Chang et al., 2016).

**FERROPTOSIS IN CARDIOMYOCYTES AFTER IRI**

Elevated concentration of the intracellular iron–induced poisonous ROS-dependent reaction is defined as ferroptosis,
which is a non-apoptotic programmed cell death and is characterized by overload iron-associated lipid peroxidation (Conrad et al., 2018). It can be initiated by either depletion of glutathione biosynthesis or inactivation of the antioxidant enzyme GPX4 that is deemed a consequence of iron-relevant ROS generation as well as polyunsaturated fatty acid (PUFA) peroxidation, contributing to the disruption of redox homeostasis (Dixon et al., 2012; Cao and Dixon, 2016). Currently, the major signaling pathways of ferroptosis are summarized in Figure 3. Moreover, recent studies have confirmed ferroptosis to be a substantial contributor to the pathogenesis of cardiomyocyte IRI, as evidenced by the protective effect on cardiomyocytes once the ferroptosis inhibitor is administered (e.g., lipoxystatin-1, Lip-1) on a MIRI model, implicating that ferroptosis might provide a novel treatment targeted for diseases associated with cardiomyocyte IRI (Diez-López et al., 2018). Therefore, the effects of ferroptosis-associated molecular pathways on MIRI are as follows.

Iron Metabolism Signaling Pathway
Iron overload resulted from either cytoplasm iron imbalance or mitochondrial iron disturbance exerts an impact on pathogenesis and progression of ferroptosis. One of the intracellular iron modulators nuclear receptor coactivator 4 (NCOA4), for example, can be regulated by ferritinophagy to further suppress transferrin exporting intracellular iron, while another key encoder named iron-responsive element-binding protein 2 (IREB2) mainly affects transferrin expression as well as iron transportation (Xie et al., 2016). Likewise, the cross talk of iron on the mitochondrial membrane is primarily regulated by the voltage-dependent anion channel (VDAC) located on the outer mitochondrial membrane (Tateda et al., 2012). VDAC 2/3 shows evident signs of opening under persistent exposure to mitochondrial iron accumulation, and this subsequently primes the response of ferroptosis via regulating the upstream protein of FtMt. Accordingly, the overexpression of FtMt can intercept mitochondrial iron to protect cells from ferroptosis (Maldonado et al., 2013).

Glutathione Metabolism Signaling Pathway
Intracellular reduced glutathione (GSH), considered the main antioxidant buffer, commonly displays the ability in protecting against lipid peroxidation in ferroptosis by donating an electron to GPX4, which can suppress the formation of iron-dependent ROS by transforming lipid hydroperoxides into lipid alcohols (Stockwell et al., 2017; Ingold et al., 2018). Originally, endogenous biosynthesis of GSH relies on the molecular substrate called cysteine, which is transferred via a heterodimeric cell membrane antipporter, system Xc- that is composed of a transmembrane protein transporter solute carrier family 7 member 11 (SLC7A11) and a single-pass transmembrane regulatory protein solute carrier family 3 member 2 (SLC3A2), regulating ferroptosis by exchanging glutamate and cystine at a 1:1 ratio (Fujii et al., 2019). Importantly, the ferroptotic inhibitor of erasin can directly restrain system Xc- function resulting in GPX4 hypoactivation due to the depletion of GSH (Hayano et al., 2016). Consistent with this finding, the knockdown of GPX4 could exasperate lipid peroxidation-mediated ferroptosis, suggesting GPX4 to be the key negative regulator of ferroptosis (Gladyshev et al., 1999).

Lipid Peroxidation Signaling Pathway
Even though the systemic antioxidant effect dominates the enzyme-linked reactions, long-term exposure to oxidative stress can inevitably trigger the biosynthesis of PUFAs in decompenylation by activating lipid metabolism-related enzymes, including acyl-coA synthetase long-chain family member 4 (ACSL4) and lysophosphatidylcholine acyltransferase 3 (LPCAT3) (Anthonymothu et al., 2018). PUFAs are catalyzed to generate subversive lipid peroxides that destruct cell morphology, such as mitochondrial membrane shrinkage and membrane imperfection, ultimately leading to ferroptosis (Ng et al., 2020). In accordance with these findings, exogenous unsaturated fatty acids might not only inhibit the susceptibility of cells to ferroptosis but also refrain the lipid bilayer of the cell membrane from oxidative injury (Magtanong et al., 2019).

NOX4 Signaling Pathway
Previous studies have regarded NADPH oxidase 4 (NOX4) to be the major molecular medium of oxidative stress in cardiomyocytes that transfers electrons from NADPH to the oxygen atom, even producing superoxide (Kuroda et al., 2010). On account of its inductive ability in peroxidation, NOX4 deficiency inhibits the cardiomyocytotoxicity and mitochondrial injury induced by produced intracellular free radicals, implying that NOX4 is compromised in oxidative stress-mediated cell damage (Sun et al., 2017). As discovered by Chen et al., the knockdown of NOX4 dramatically reversed ventricular remodeling by means of improving iron overload in the heart failure model, which further inferred pharmaceutical inhibition or knockout of GPX4 to be effective in precaution of ferroptosis (Chen et al., 2019). Remarkably, apoptosis-inducing factor mitochondrion-associated 2 (AIFM2, also named FSP1) is another electronic carrier and lipid-soluble antioxidant independent of GPX4, which acts as a nicotinamide adenine dinucleotide phosphate (NADP)–dependent coenzyme Q (CoQ) oxidoreductase to suppress ferroptosis by directly modulating the CoQ antioxidant system (Marshall et al., 2005).

ATF4 Signaling Pathway
Activating transcription factor 4 (ATF4) has been documented to involve in the regulation of autophagy, oxidative stress, and inflammatory response, and partially expresses at a low level under the normal condition, whereas it is dramatically overexpresses upon stimulation with hypoxia or ERS (Pitale et al., 2017). A recent report revealed that activation of the ATF4-C/EBP homologous protein (CHOP) signaling pathway was closely related to ferroptosis-associated diseases such as cardiomyocyte IRI by modulating the ATF4-targeting gene of CHAC1 to induce GSH degradation (Chen et al., 2017a; Wang et al., 2019; Li et al., 2020). Based on the capacity of heat shock protein 5 (HSP5) in mediating endoplasmic reticulum unfolding of the protein to negatively regulate GPX4, induction of HSP5 expression can feedback on the
upregulation of ATF4 activity to elevate the GPX4 level, eventually preventing cells from ferroptosis (Bai et al., 2020). Therefore, cascaded signals of ATF4-HSPA5-GPX4 implicated in oxidative response and the metabolic system might act as a negative feedback on ferroptosis via complex networks (Zhu et al., 2017).

**NRF2 Signaling Pathway**

A transcription factor in terms of nuclear factor erythroid 2–related factor 2 (NRF2) can mechanistically regulate ferroptosis by not only promoting iron storage to reduce iron accumulation, but also upregulating SLC7A11 activity to increase glutamate content (Fan et al., 2017; Kerins and Ooi, 2018; Mou et al., 2019). Meanwhile, NRF2 is modulated by upstream molecules, such as P62 and alternative reading frame (ARF). P62 likely suppresses the degradation of NRF2 to further enhance nuclear reservation, whereas ARF directly inhibits transcriptional function targeting to downregulate SLC7A11 expression; both of them effectively prevent ferroptosis (Sun et al., 2016; Chen et al., 2017b). Likely, ferroptosis-associated FT, together with heme oxygenase (HO-1), is affected by NRF2 as evidence showed that HO-1 knockdown deteriorated erastin-induced ferroptosis, but NRF activation might inversely upregulate HO-1 (Gai et al., 2020). Collectively, NRF2 is identified to be the main negative mediator in signaling cross-connection for protecting the cell against ferroptosis.

Since the viewpoint that abundant iron deposited on cardiac cells in the MIRI mouse model to induce ferroptosis was first recognized by Bata et al., it led us to further investigate the link between ferroptosis and cardiomyocyte IRI (Baba et al., 2018) (Figure 4). Oxidative stress plays the predominant role in cardiomyocyte IRI that is manifested by chronic inflammation in vascular walls and lipid peroxidation deposition in the arterial wall (Berliner, 2002). Theoretically, membrane phospholipid compounds of PUFA’s exhibit high susceptibility to eстерification as evidenced by the signs on phospholipid oxidation products and subsequent damage via the production of ROS onset of MIRI (White et al., 2015). With continually increasing species of oxidized lipoacylcholine being discovered during cardiomyocyte IRI, the mechanisms underlying lipid peroxidation have been confirmed to be the connection between ferroptosis and MIRI (Yeang et al., 2019). Moreover, the exogenous supplement of these oxidized lipid products to cardiomyocytes can definitely trigger ferroptosis-associated cell death; thus, ferroptosis regulates cardiomyocyte IRI by affecting phospholipid metabolism (Ganguly et al., 2018).

The iron-related signaling pathway is recognized to be another prerequisite for ferroptosis-mediated cardiomyocyte IRI secondary to lipid oxidative stress, which might be attested by the protective effect of the iron chelator called deferoxamine in suppressing cardiac cells from ferroptosis by means of binding iron in an MIRI model (Kakhlon and Cabantchik, 2002; Gao et al., 2015). A previous study confirmed iron to be an indispensable substrate for NADPH oxidase that was capable of catalyzing to produce superoxides, finally initiating ferroptosis (Dixon and Stockwell, 2014). Consistently, ferroptosis-mediated...
TABLE 2 | Ferroptosis initiators and inhibitors: targeting strategy for MIRI.

| Reagent          | Effects     | Targets          | Key mechanisms                                      | References                                      |
|------------------|-------------|------------------|----------------------------------------------------|-------------------------------------------------|
| Erastin          | Induction   | System Xc-       | GSH depletion and GPX4 inactivation                | Yagoda et al. (2007); Yang et al. (2014)        |
| RSL3             | Induction   | GPX4             | Blends GPX4 protein and increases ROS generation   | Huang et al. (2021)                             |
| BSO              | Induction   | System Xc-       | Suppresses peripheral GSH biosynthesis             | Harris et al. (2015)                            |
| Lanperisone      | Induction   | System Xc-       | Promotes ROS production                            | Shaw et al. (2011)                              |
| Sorafenib        | Induction   | System Xc-       | Interdicts GSH biosynthesis                        | Zhang et al. (2013); Louandre et al. (2015)     |
| Sulfasalazine    | Induction   | System Xc-       | Downregulates SLC7A11 expression                   | Sehm et al. (2016)                              |
| DPI 7,10, 12     | Induction   | GPX4             | Blends GPX4 and augments ROS production.            | Sharma and Flora, (2021)                        |
| Ferrostatin-1    | Inhibition  | ROS              | Prevents ROS generation                            | Yin et al. (2011)                               |
| Liproxstatin-1   | Inhibition  | ROS              | Prevents lipid peroxidation                         | Zhang et al. (2016)                             |
| Zielonut         | Inhibition  | 5-Lipoxygenase   | Inhibits PUFAs catalyzing into hyperoxide           | Kagan et al. (2017)                             |
| Vitamin E        | Inhibition  | 5-Lipoxygenase   | Inhibits PUFAs catalyzing into hyperoxide           | Liu et al. (2015)                               |
| Deferoxamine     | Inhibition  | Fe²⁺             | Chelates intracellular superfluous iron            | Doll and Conrad, (2017)                         |
| XJB-5-131        | Inhibition  | ROS              | Eliminates poisonous ROS                           | Doll and Conrad, (2017)                         |
| Mitroquinone     | Inhibition  | ROS              | Eliminates mitochondrial ROS                       | Fuchs and Steller, (2011)                       |

One type of inducers shows efficacy in inhibiting GPX4 activity by GSH depletion including erastin, sulfasalazine, diphenyleneiodonium chloride 2 (DPI2), buthionine sulfoximine (BSO), and lanperisone, while another form of inducers mainly directly blocks GPX4 without GSH consumption, such as RSL3 and DPI family except for DPI2. Mechanistically, erastin triggers ferroptosis either by combining mitochondrial VDAC2/3 to disrupt the respiratory chain together with ROS accumulation or weakening Xc system activity to attenuate GSH concentration accompanied by GPX4 inactivation (Yagoda et al., 2007; Yang et al., 2014). RSL3, impervious to the upstream of GPX4 including GSH depletion and cysteine intussuscepts, is able to inactivate GPX4 by the binding protein site, in turn augmenting ROS generation to initiate ferroptosis (Huang et al., 2021). On account of the succedaneous antioxidant approach upregulated by blocking GSH synthesis, BSO, owning pericellular capacity in suppressing peripheral GSH biosynthesis and eventually inactivating GPX4 to induce ferroptosis, exhibits lower efficacy on occasioning ferroptosis-related chain reaction than RSL3 (Harris et al., 2015). Although lanperisone can effectively enhance ROS production mediated by the RAS/MEK/ERK signaling pathway to induce ferroptosis due to KRAS gene mutation in embryonic fibroblasts, it displays less competency than erastin in resisting against KRAS-driven tumor vitality (Shaw et al., 2011).

Similar to the reagent of erastin, sorafenib, a multikinase inhibitor utilized for hepatic cancer therapy, interdicts GSH biosynthesis, rather than Raf suppression, and induces ferroptosis in tumor cells manifested as attenuation in tumor angiogenesis and restriction in tumor proliferation (Zhang et al., 2013; Louandre et al., 2015). Sulfasalazine authorized by the drug institution for nonbacterial inflammatory treatment was also confirmed to be applied to induce ferroptosis in gliofibroma cells by downregulating SLC7A11 expression (Sehm et al., 2016). Except for DPI2 which initiates ferroptosis conformed to erastin-associated mechanism, other members of DPI directly induce ferroptosis targeting for GPX4, instead of GSH reduction (Sharma and Flora, 2021).

upregulation of NADPH oxidase and monocyte adhesion might account for cardiomyocyte IRI due to endothelial dysfunction following reperfused stress, hinting that the iron metabolism–associated pathway belongs to the leading cause for ferroptosis involved in MIRI (Sullivan, 2009; Kuo et al., 2014). The aforementioned notions were further validated by the subsequent fluorescence confocal analysis of cardiac muscle tissue from the MIRI mouse model, which manifested redundant iron accumulation and even non-apoptotic cell death of ferroptosis, showing an improved appearance after administration of ferrostatin-1 (Fer-1) (Stamenkovic et al., 2021). Moreover, rapamycin, discovered remarkably efficacious in regulating MIRI that need to be further clarified.

INITIATORS AND INHIBITORS OF FERROPTOSIS AS THE POTENTIAL TARGETS FOR MIRI

Initiators of Ferroptosis

Depending on whether directly targeting for GPX4 activity, all the ferroptotic initiators are classified into two categories (Table 2). One type of inducers shows efficacy in inhibiting GPX4 activity by GSH depletion including erastin, sulfasalazine, diphenyleneiodonium chloride 2 (DPI2), buthionine sulfoximine (BSO), and lanperisone, while another form of inducers mainly directly blocks GPX4 without GSH consumption, such as RSL3 and DPI family except for DPI2. Mechanistically, erastin triggers ferroptosis either by combining mitochondrial VDAC2/3 to disrupt the respiratory chain together with ROS accumulation or weakening Xc system activity to attenuate GSH concentration accompanied by GPX4 inactivation (Yagoda et al., 2007; Yang et al., 2014). RSL3, impervious to the upstream of GPX4 including GSH depletion and cysteine intussuscepts, is able to inactivate GPX4 by the binding protein site, in turn augmenting ROS generation to initiate ferroptosis (Huang et al., 2021). On account of the succedaneous antioxidant approach upregulated by blocking GSH synthesis, BSO, owning pericellular capacity in suppressing peripheral GSH biosynthesis and eventually inactivating GPX4 to induce ferroptosis, exhibits lower efficacy on occasioning ferroptosis-related chain reaction than RSL3 (Harris et al., 2015). Although lanperisone can effectively enhance ROS production mediated by the RAS/MEK/ERK signaling pathway to induce ferroptosis due to KRAS gene mutation in embryonic fibroblasts, it displays less competency than erastin in resisting against KRAS-driven tumor vitality (Shaw et al., 2011).

Similar to the reagent of erastin, sorafenib, a multikinase inhibitor utilized for hepatic cancer therapy, interdicts GSH biosynthesis, rather than Raf suppression, and induces ferroptosis in tumor cells manifested as attenuation in tumor angiogenesis and restriction in tumor proliferation (Zhang et al., 2013; Louandre et al., 2015). Sulfasalazine authorized by the drug institution for nonbacterial inflammatory treatment was also confirmed to be applied to induce ferroptosis in gliofibroma cells by downregulating SLC7A11 expression (Sehm et al., 2016). Except for DPI2 which initiates ferroptosis conformed to erastin-associated mechanism, other members of DPI directly induce ferroptosis targeting for GPX4, instead of GSH reduction (Sharma and Flora, 2021).
Inhibitors of Ferroptosis

Most varieties of ferroptotic inhibitors consist of antioxidants (e.g., Fer-1, Lip-1, and vitamin E), iron chelators (e.g., defereroxamine), and ROS scavengers (e.g., N-acetyl-L-cysteine, XJB-5-131, JP4-039, and mitoquinone), and they can potentially resist ferroptosis induced by RSL3 or erastin (Friedmann Angeli et al., 2014; Boonnoy et al., 2017; Zilka et al., 2017; Skouta et al., 2014; Krainz et al., 2016) (Table 2). Commonly, both Fer-1 and Lip-1, failing to suppress peroxidase activity, are able to capture free radicals to ameliorate ROS deposition, rather than inhibit ferroptosis as evidenced by the beneficial impact on the model of I/R injury (Yin et al., 2011; Zhang et al., 2019b). Based on the oxidant function of LOX in catalyzing unsaturated fatty acids into hyperoxides, the LOX inhibitor of zileuton and vitamin E antioxidant together with tocotrienol might protect cells from ferroptosis-induced oxidative stress (Liu et al., 2015; Kagan et al., 2017). Additionally, pretreatment of cells with deferoxamine, which chelates continuous iron, may contribute to protecting cells against ferroptosis by disturbing the ROS-mediated Fenton reaction (Doll and Conrad, 2017). Currently, novel synthetic compounds defined as ROS scavengers, including XJB-5-131 and JP4-039, are reported to markedly suppress ferroptosis via eliminating poisonous ROS. In fact, the mitochondrion is considered the first line of defense in ROS clearance, and consequently, mitoquinone targets for mitochondrial ROS elimination (Fuchs and Steller, 2011).

CONCLUSION AND PERSPECTIVES

Cardiomyocyte IRI is commonly yet severely complicated by myocardial reperfusion intervention but is prone to be neglected in the clinical practice. The interplay between disorder of energy metabolism and massive accumulation of oxygen free radicals drives cardiomyocytes into a vicious circle in the setting of MIRI. Together with vascular endothelial inflammation, oxidative stress depending on iron homeostasis imbalance can damage cardiac function due to myocardial remodeling. Therefore, early interference of MIRI plays a critical role in the survival and prognosis of myocardial ischemia. Despite mechanisms with regard to ferroptosis in MIRI diseases being continually explored in experimental research studies and many progresses being achieved in clinical practice, certain limitations however remain to be overcome. First, precise downstream molecules of the signaling pathway in lipid peroxidation regulating ferroptotic myocardial remodeling appear unclear. Second, the potential mechanism of ferroptosis to activate the systematic inflammatory response in MIRI needs to be further explored. Third, more reasonable clinical trials are essential to be conducted in order to verify the outcomes in the established animal models of ferroptosis-related MIRI. In summary, ferroptosis appears to play an important role in pathogenic progression of MIRI; thus, targeting ferroptosis might provide a potential therapy for MIRI-associated diseases in the future.

AUTHOR CONTRIBUTIONS

J-YL conducted the literature review and drafted the manuscript, S-QL and R-QY helped with preparing the manuscript, which J-YL conducted the literature review and drafted the manuscript, and S-QL and R-QY helped with preparing the manuscript. All authors read and approved the final manuscript.

REFERENCES

Aisen, P., Enns, C., and Wessling-Resnick, M. (2001). Chemistry and Biology of Eukaryotic Iron Metabolism. Int. J. Biochem. Cell Biol. 33, 940–959. doi:10.1016/s1357-2725(01)00063-2
Anthonymuthu, T. S., Kenny, E. M., Shrivastava, I., Tyurina, Y. Y., Hier, Z. E., Ting, H.-C., et al. (2018). Empowerment of 15-Lipoxygenase Catalytic Competence in Selective Oxidation of Membrane ETE-PE to Ferroptotic Death Signals, HpETE-PE. J. Am. Chem. Soc. 140, 17835–17839. doi:10.1021/jacs.8b09913
Baba, Y., Higa, J. K., Shimada, B. K., Horizumi, K. M., Suhara, T., Kobayashi, M., et al. (2018). Protective Effects of the Mechanistic Target of Rapamycin against Excess Iron and Ferroptosis in Cardiomyocytes. Am. J. Physiol. Heart Circulatory Physiol. 314, H659-H668. doi:10.1152/ajpheart.00452.2017
Bai, T., Liang, R., Zhu, R., Wang, W., Zhou, L., and Sun, Y. (2020). MicroRNA-214-3p Enhances Erastin-induced Ferroptosis by Targeting ATF4 in Hepatoma Cells. J. Cell Biol. 235, 5637–5648. doi:10.1083/jcb.20192496
Bayeva, M., Khekchaduri, A., Puig, S., Chang, H.-C., Patali, S., Blackshear, P. J., et al. (2012). mTOR Regulates Cellular Iron Homeostasis through Tristetraprolin. Cell Metab. 16, 645–657. doi:10.1016/j.cmet.2012.10.001
Bell, R. M., and Yellon, D. M. (2011). There Is More to Life Than Revascularization: Therapeutic Targeting of Myocardial Ischemia/reperfusion Injury. Cardiovasc. Ther. 29, e67–e79. doi:10.1111/j.1755-3922.2010.00190.x
Berlin, J. (2002). Lipid Oxidation Products and Atherosclerosis. Vasc. Pharmacol. 38, 187–191. doi:10.1016/S1537-1891(02)00168-4
Boag, S. E., Andreano, E., and Spyridopoulos, I. (2017). Lymphocyte Communication in Myocardial Ischemia/reperfusion Injury. Antioxid. Redox Signal. 26, 660–675. doi:10.1089/ars.2016.6940
Boonnoy, P., Karttunen, M., and Wong-Ekkabut, J. (2017). Alpha-tocopherol Inhibits Pore Formation in Oxidized Bilayers. Phys. Chem. Chem. Phys. 19, 5699–5704. doi:10.1039/c6cp08051k
Cadenas, S. (2018). ROS and Redox Signaling in Myocardial Ischemia-Reperfusion Injury and Cardioprotection. Free Radic. Biol. Med. 117, 76–89. doi:10.1016/j.freeradbiomed.2018.01.024
Campanella, A., Rovelli, E., Santambrogio, P., Cozzi, A., Taroni, F., and Levi, S. (2009). Mitochondrial Ferritin Limits Oxidative Damage Regulating Mitochondrial Iron Availability: Hypothesis for a Protective Role in Friedreich Ataxia. Hum. Mol. Genet. 18, 1–11. doi:10.1093/hmg/ddn308
Cao, J. Y., and Dixon, S. J. (2016). Mechanisms of Ferroptosis. Cell. Mol. Life Sci. 73, 2195–2209. doi:10.1007/s00018-016-2194-1
Chan, S., Lian, Q., Chen, M.-P., Jiang, D., Ho, J. T. K., Cheung, Y.-F., et al. (2018). Deferiprone Inhibits Iron Overload-Induced Tissue Factor Bearing Endothelial Microparticle Generation by Inhibition Oxidative Stress Induced Mitochondrial Injury, and Apoptosis. Toxicol. Appl. Pharmacol. 338, 148–158. doi:10.1016/j.taap.2017.11.005

FUNDING

This study was supported by the grants from the National Natural Science Foundation of China (Nos. 81730057, 82130062, and 81873946), the National Tutorial System Training Program of Suzhou (2020-12), and the Provincial Key Project of Medical Science Research of Hebei (No. 20210013).
Tateda, C., Kusano, T., and Takahashi, Y. (2012). The Arabidopsis Voltage-dependent Anion Channel 2 is Required for Plant Growth. Plant Signal. Behav. 7, 31–33. doi:10.4161/psb.7.1.18394

Tian, L., Cao, W., Yue, R., Yuan, Y., Guo, X., Qin, D., et al. (2019). Pretreatment with Tilanin Improves Mitochondrial Energy Metabolism and Oxidative Stress in Rats with Myocardial Ischemia/reperfusion Injury via AMPK/SIRT1/PGC-1α Alpha Signaling Pathway. J. Pharmacol. Sci. 139, 352–360. doi:10.1016/j.jphs.2019.02.008

Turer, A. T., and Hill, J. A. (2010). Pathogenesis of Myocardial Ischemia-Reperfusion Injury and Rationale for Therapy. Am. J. Cardiol. 106, 360–368. doi:10.1016/j.amjcard.2010.03.032

Valko, M., Jomova, K., Rhodes, C. J., Kuca, K., and Musilek, K. (2016). Redox- and Non-redox-metal-induced Formation of Free Radicals and Their Role in Human Disease. Arch. Toxicol. 90, 1–37. doi:10.1007/s00204-015-1579-5

Vela, D. (2020). Keeping Heart Homeostasis in Check through the Balance of Iron Metabolism. Acta Physiol. 228, e13324. doi:10.1111/apha.13324

Verkhratsky, A., and Parpura, V. (2014). Calcium Signalling and CalciumChannels: Evolution and General Principles. Eur. J. Pharmacol. 739, 1–3. doi:10.1016/j.ejphar.2013.11.013

Vinten-Johansen, J., Jiang, R., Reeves, J. G., Mykytenko, J., Deneve, J., and Jobe, L. J. (2007). Inflammation, Proinflammatory Mediators and Myocardial Ischemia-Reperfusion Injury. Hematol. Oncol. Clin. North Am. 21, 123–145. doi:10.1016/j.hoc.2006.11.010

Wang, Y.-Q., Chang, S.-Y., Wu, Q., Gou, Y.-J., Jia, L., Cai, Y.-M., et al. (2016). The Protective Role of Mitochondrial Ferritin on Erastin-Induced Ferroptosis. Front. Aging Neurosci. 8, 308. doi:10.3389/fnagi.2016.00308

Wang, N., Zeng, G.-Z., Yin, J.-L., and Bian, Z.-X. (2019). Artesunate Activates the ATF4-CHOP-CHAC1 Pathway and Affects Ferroptosis in Burkitt’s Lymphoma. Biochem. Biophys. Res. Commun. 519, 533–539. doi:10.1016/j.bbrc.2019.09.023

Watt, R. K. (2013). A Unified Model for Ferritin Iron Loading by the Catalytic center: Implications for Controlling “Free Iron” during Oxidative Stress. ChemBioChem 14, 415–419. doi:10.1002/cbic.201200783

White, C. W., Hasanally, D., Mundh, P., Li, Y., Xiang, B., Klein, J., et al. (2015). A Whole Blood-Based Perfusate Provides Superior Preservation of Myocardial Function during Ex Vivo Heart Perfusion. J. Heart Lung Transplant. 34, 113–121. doi:10.1016/j.healun.2014.09.021

Williams, R. E., Zweier, J. L., and Flaherty, J. T. (1991). Treatment with Deferoxamine during Ischemia Improves Functional and Metabolic Recovery and Reduces Reperfusion-Induced Oxygen Radical Generation in Rabbit Hearts. Circulation 83, 1006–1014. doi:10.1161/01.cir.83.3.1006

Wofford, J. D., Chakrabarti, M., and Lindahl, P. A. (2017). Mössbauer Spectra of Mouse Hearts Reveal Age-dependent Changes in Mitochondrial and Ferritin Iron Levels. J. Biol. Chem. 292, 5546–5554. doi:10.1074/jbc.M117.777201

Wood, J. C. (2008). Cardiac Iron across Different Transfusion-dependent Diseases. Blood Rev. 22 (Suppl. 2), S14–S21. doi:10.1016/S0268-960X(08)70004-3

Wu, W., Chang, S., Wu, Q., Xu, Z., Wang, P., Li, Y., et al. (2016). Mitochondrial Ferritin Protects the Murine Myocardium from Acute Exhaustive Exercise Injury. Cell Death Dis 7, e2475. doi:10.1038/cddis.2016.372

Xie, Y., Hou, W., Song, X., Yu, Y., Huang, J., Sun, X., et al. (2016). Ferroptosis: Process and Function. Cell Death Differ. 23, 369–379. doi:10.1038/cdd.2015.158

Yagoda, N., von Rechenberg, M., Zaganjor, E., Bauer, A. J., Yang, W. S., Fridman, D. J., et al. (2007). RAS-RAF-MEK-dependent Oxidative Cell Death Involving Voltage-dependent Anion Channels. Nature 447, 865–869. doi:10.1038/nature05859

Yang, W. S., SiriRamaratnam, R., Welsch, M. E., Shimada, K., Skouta, R., Viswanathan, V., et al. (2014). Regulation of Ferroptotic Cancer Cell Death by GPX4. Cell 156, 317–331. doi:10.1016/j.cell.2013.12.010

Yang, F., Qin, Y., Lv, J., Wang, Y., Che, H., Chen, X., et al. (2018). Silencing Long Non-coding RNA Kcnq1ot1 Alleviates Pyroptosis and Fibrosis in Diabetic Cardiomyopathy. Cell Death Dis. 9, 1000. doi:10.1038/s41419-018-1029-4

Yeang, C., Hasanally, D., Que, X., Hung, M.-Y., Stamenkovic, A., Chan, D., et al. (2019). Reduction of Myocardial Ischaemia-Reperfusion Injury by Inactivating Oxidized Phospholipids. Cardiovasc. Res. 115, 179–189. doi:10.1093/cvr/cvy136

Yin, H., Xu, L., and Porter, N. A. (2011). Free Radical Lipid Peroxidation: Mechanisms and Analysis. Chem. Rev. 111, 5944–5972. doi:10.1021/cr200084x

Zhang, L., Gong, F., Zhang, F., Ma, J., Zhang, P. D., and Shen, J. (2013). Targeted Therapy for Human Hepatic Carcinoma Cells Using Folate-Functionalized Polymeric Micelles Loaded with Superparamagnetic Iron Oxide and Soranefib In Vitro. Int. J. Nanomedicine 8, 1517–1524. doi:10.2147/IJN.S43263

Zhang, Y., Liu, D., Hu, H., Zhang, P., Xie, R., and Cui, W. (2019). HIF-1α/BNIP3 Signaling Pathway-Induced-Autophagy Plays Protective Role during Myocardial Ischemia-Reperfusion Injury. Biomed. Pharmacother. 120, 109464. doi:10.1016/j.biopha.2019.109464

Zhang, Y., Sun, C., Zhao, C., Hao, J., Zhang, Y., Fan, B., et al. (2019). Ferroptosis Inhibitor SRS 16-86 Attenuates Ferroptosis and Promotes Functional Recovery in Contusion Spinal Cord Injury. Brain Res. 1706, 48–57. doi:10.1016/j.brainres.2018.10.023

Zhou, T., Chuang, C.-C., and Zuo, L. (2015). Molecular Characterization of Reactive Oxygen Species in Myocardial Ischaemia-Reperfusion Injury. Biomed. Res. Int. 2015, 1–9. doi:10.1155/2015/864946

Zhu, S., Zhang, Q., Sun, X., Zeh, H. J., Lotze, M. T., Kang, R., et al. (2017). HSPA5 Regulates Ferroptotic Cell Death in Cancer Cells. Cancer Res. 77, 2064–2077. doi:10.1158/0008-5472.CAN-16-1979

Zilka, O., Shah, R., Li, B., Friedmann Angeli, J. P., Grieser, M., Conrad, M., et al. (2017). On the Mechanism of Cytoprotection by Ferrostatin-1 and Liproxstatin-1 and the Role of Lipid Peroxidation in Ferroptotic Cell Death. ACS Cent. Sci. 3, 232–243. doi:10.1021/acscentsci.7b00028

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Li, Liu, Yao, Tian and Yao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
GLOSSARY

ABCB8, ATP-binding cassette subfamily B member 8;
ACSL4, acyl-coA synthetase long-chain family member 4;
AIFM2, apoptosis-inducing factor mitochondrion-associated 2;
ATF4, activating transcription factor 4;
ARF, alternative reading frame;
BSO, buthionine sulfoximine
CHOP, C/EBP homologous protein;
CoQ, coenzyme Q;
DMT-1, divalent metal transporter 1;
DPI2, diphenyleneiodonium chloride 2;
ERS, endoplasmic reticulum stress;
Fer-1, ferrostatin-1;
FPN, ferroportin;
FtMt, mitochondrial ferritin;
FT, ferritin;
FTH, ferritin heavy chain;
FTL, ferritin light chain;
GSH, glutathione;
GPX4, glutathione peroxidase 4;
HO, hydroxyl radicals;
HO-1, heme oxygenase;
HIF, hypoxia-inducible factor;
HSPA5, heat shock protein five;
IRP, iron regulatory proteins;
IRE, iron-responsive elements;
IRI, ischemia-reperfusion injury;
ISCs, iron–sulfur clusters;
IREB2, element-binding protein 2;
LIP, labile iron pool;
Lip-1, liproxstatin-1;
LPCAT3, lysophosphatidylcholine acyl transferase 3;
MIRI, myocardial ischemia-reperfusion injury;
mTOR, mammalian target of rapamycin;
mPTP, mitochondrial permeability transition pore;
MCU, mitochondrial calcium uniporter;
MFRN, mitoferrin 2;
MMP, mitochondrial membrane potential;
NADP+, nicotinamide adenine dinucleotide phosphate;
NCOA4, nuclear receptor coactivator 4; I
NOX4, NADPH oxidase 4;
PUFAs, polyunsaturated fatty acids;
ROS, reactive oxygen species;
SLC7A11, solute carrier family seven member 11;
SLC3A2, solute carrier family three member 2;
TfR1, transferring receptor 1;
VDAC, voltage-dependent anion channel;